secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caris Life Sciences, Inc. (CAI)
CIK:        0002019410
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0002019410-25-000011
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caris Life Sciences Q2 2025 revenue $181.4M (+81% YoY); Adj. EBITDA positive $16.7M; FY rev guidance $675-685M
--------------------------------------------------------------------------------

- Total revenue $181.4M, up 81.3% YoY; gross margin 62.7% vs 37.5% a year ago.
- Net loss $71.8M includes $37.1M one-time IPO conversion expense; positive Adj. EBITDA $16.7M and positive free cash flow $5.9M.
- Clinical therapy selection volume 50,032 cases (+22% YoY); MI Profile volume +17.7%, Caris Assure volume +56.3%.
- FY2025 revenue guidance $675-685M (64-66% growth); clinical volume growth expected 19-21%.
- Recent IPO raised $519.5M net; cash and securities $724.9M at June 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2019410/000201941025000011/0002019410-25-000011-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2019410/000201941025000011/cai-20250812.htm
  HTML page:      https://secwatch.observer/filing/0002019410-25-000011

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer